Drug Profile


Alternative Names: BMS-284756; Des-6-quinolone; Desquinolone; Garenoxacin mesylate; Garenoxacin mesylate film-coated tablets; Garenoxacin mesylate solution for infusion; Geninax; Inforce; T 3811ME; T-3811

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taisho Pharmaceutical; Toyama Chemical
  • Developer Merck & Co; Taisho Pharmaceutical; Toyama Chemical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Gram-positive infections; Otorhinolaryngological infections; Respiratory tract infections
  • Preregistration Bacterial infections
  • Discontinued Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Intra-abdominal infections; Skin and soft tissue infections

Most Recent Events

  • 16 Sep 2016 Astellas Pharma in collaboration with Taisho Toyama Pharmaceutical completes the GARIREO study for Respiratory tract infections in Japan (PO) (UMIN000016373)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Bacterial-infections in Japan (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Gram-negative-infections in Japan (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top